Core Viewpoint - The pharmaceutical sector experienced a decline in early trading, with various indices reflecting negative performance, while the Hang Seng Innovation Drug ETF saw significant net subscriptions, indicating investor interest despite the overall downturn [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovation Drug Index fell by 2.6% [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 2.2% [1] - The CSI Innovation Drug Industry Index dropped by 0.5% [1] - The CSI Biotechnology Theme Index declined by 0.6% [1] - The CSI 300 Pharmaceutical and Health Index fell by 0.8% [1] Group 2: Investment Activity - The Hang Seng Innovation Drug ETF (159316) recorded over 60 million net subscriptions, showing resilience against market trends [1] - The ETF attracted more than 900 million yuan in inflows during the month, ranking among the top in Hong Kong's innovation drug-related products [1]
医药板块早盘回调，恒生创新药ETF（159316）逆势获超6000万份净申购
Mei Ri Jing Ji Xin Wen·2025-10-22 04:53